Over the past few months, UPM has received manufacturing site approvals from several global health authorities, including:
Russia: The Ministry of Industry and Trade of the Russian Federation
Turkey: Turkish Medicines and Medical Device Agency (TMMDA)
Japan: Pharmaceuticals and Medical Devices Agency (PMDA)
Brazil: Agência Nacional de Vigilância Sanitária (ANVISA)
India: Central Drugs Standard Control Organization (CDSCO)
With these additions, UPM now holds approved manufacturing status in 12 countries worldwide.
"These approvals reflect the strength of our quality systems and the consistency of our manufacturing practices across global markets," said Greg Jones, CEO of UPM Pharmaceuticals.
Each new approval represents months of rigorous preparation, documentation, and inspection by our regulatory and quality teams. Their expertise and dedication have been instrumental in achieving these milestones while maintaining our existing certifications.
As we expand our global reach, we remain focused on what matters most: delivering reliable, high-quality pharmaceutical development and manufacturing to partners worldwide.
